More Articles

Market Access

All Over the Map

Dr Nicola Davies, (Mar 3, 2017)

How can pharma meet the needs of payers in such a fragmented landscape?

A Marriage Made in Heaven

Adam Hill, (Mar 2, 2017)

Patient groups and pharma may have the same goal - better health outcomes - but managing the relationships needs care
Market Access

R&D Gets Real with Real-World Evidence

Danielle Barron, (Mar 1, 2017)

Bringing RWE into the earlier stages of R&D needs a collective effort from companies, regulators and other stakeholders

You’ve Got to Mean It

Danielle Barron, (Feb 28, 2017)

Patient involvement in research is increasing but pharma needs to get serious to create genuinely meaningful relationships.

The Consumer Revolution

Hugh Gosling, (Feb 28, 2017)

As industry truly starts to listen and react to the voices of the people who take its medicines, a more nuanced, insightful picture is emerging about what patients want from pharma and its medicines

Driving Change: Focusing on the Long-Term

Nicola Davies, (Feb 23, 2017)

Do you know how the industry will look in 15 or 20 years, and are you prepared for that future?
Market Access

Face Value

Danielle Barron, (Feb 21, 2017)

With oncology drug prices under intense and growing scrutiny, how are companies proving the value of their medicines?
Market Access

Strength in Numbers

Danielle Barron, (Feb 20, 2017)

R&D innovation is being accelerated through the nurturing of a ground breaking public-private relationship
Market Access

Access All Areas

Deirdre Coleman, (Feb 15, 2017)

Numerous barriers impede the full realization of benefit from Real World Evidence

One Giant Leap for Medical Affairs

Deirdre Coleman, (Feb 14, 2017)

Pharma’s engine of growth lies firmly within Medical Affairs and its ability to partner effectively with other functions.